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ABSTRACT 
BACKGROUND:  Reliable biomarkers for early detection of hepatocellular carcinoma (HCC) in 
patients with cirrhosis are lacking. We evaluated the use of miR-122, alpha-fetoprotein (AFP) and 
protein induced by vitamin k absence/antagonist II (PIVKA-II) for HCC risk prediction in patients with 
HBV-related cirrhosis under surveillance.  
METHODS: We first analyzed a group of 63 patients with HBV-related liver cirrhosis of whom 33 
had HCC. Then we performed a retrospective analysis on another group of 13 cirrhotic patients who 
developed HCC during surveillance, of whom serial serum samples were available (at time of HCC 
diagnosis [T0], 6-9 months [T-1] and 12-18 months [T-2] before HCC detection). Serum miR-122 levels 
were assessed by quantitative real time-PCR, whereas AFP and PIVKA-II were measured by fully 
automated chemiluminescent enzyme immunoassay.  
RESULTS: Serum levels of miR-122, AFP and PIVKA-II were different between patients with 
cirrhosis and those with HCC (P=0.024, P<0.001 and P<0.001, respectively). Areas under the curve 
(AUC) were 0.675 for miR-122, 0.791 for AFP and 0.846 for PIVKA-II, while their combination 
improved the discrimination power between cirrhosis and HCC (AUC=0.918). In the longitudinal 
study, we found a significant variation overtime for the biomarkers combination (P=0.011) but not for 
each single biomarker (miR-122, P=0.163; AFP, P=0.170; PIVKA-II, P=0.447). Combined miR-
122+AFP+PIVKA-II adjusted Hazard Ratio for HCC development was 10.63, 95% confidence interval 
1.87-60.28 (P<0.001).  
CONCLUSIONS: In HBV-related cirrhosis, the combination of  miR-122, AFP and PIVKA-II 
enables the identification of patients at higher risk of HCC development that could benefit from closer 
monitoring. 
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The natural history of chronic hepatitis B virus (HBV) infection is characterized by a chronic 
inflammation that leads to fibrosis progression and to cirrhosis, a condition at high risk for 
hepatocellular carcinoma (HCC) development.1, 2 Moreover, HBV infection represents an additional 
risk factor due to the direct oncogenic properties of the virus.3, 4  
Currently, surveillance programs for HCC detection in high risk population are mainly based on 
abdominal ultrasonography (US). According to the European Association for the Study of the Liver 
and the American Association for the Study of Liver Diseases clinical guidelines for HCC 
management, surveillance should be performed every 6 months by US, while diagnosis should be based 
on imaging methods, such as computed tomography (CT) and magnetic resonance imaging (MRI), 
and/or biopsy.5, 6 Beside imaging methods, the Japan Society of Hepatology and the Asian Pacific 
Association for the Study of the Liver guidelines suggest the use of serum biomarkers such as alpha-
fetoprotein (AFP) and des-gamma-carboxy-prothrombin (DCP), also known as protein induced by 
vitamin k absence or antagonist II (PIVKA-II), for surveillance programs and for early HCC 
detection.7, 8  
Several studies investigating the accuracy for HCC detection of either traditional biomarkers 
measured by novel highly sensitive methods or novel classes of biomarkers involved in epigenetic 
machinery (i.e. microRNAs [miRNAs]) reported promising results.9-11 Moreover, the combination of 
different biomarkers with demographic or clinical data into scores permitted to further enhance 
diagnostic accuracy, providing to clinicians potential tools to improve the management of patients at 
risk of HCC.12, 13  
In the last decade, the role of miRNAs in HCC and liver disease progression has been intensely 
investigated.14-16 In particular miR-122, a liver-specific miRNA that accounts for more than 70% of the 
total hepatic miRNA pool, has been implicated in different molecular pathways.17 Recently, it has been 
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reported that among selected miRNAs, only miR-122 serum levels varied significantly between 
patients with HBV-HCC and those with HBV-cirrhosis without HCC.18  
The aim of the present proof-of-concept study was to explore the performance of miR-122, AFP 
and PIVKA-II, alone or in combination, for HCC prediction in patients with HBV-related cirrhosis on 
long term follow up. 
 
Materials and methods 
Study population 
The study involved a cross-sectional and a longitudinal cohort of hepatitis B surface antigen 
(HBsAg)-positive patients on follow-up between June 2012 and December 2015.  
Inclusion criteria were: age between 18 and 80 years, HBsAg-positivity, signed written 
informed consent. Exclusion criteria included: anti-HCV-positivity, anti-HIV-positivity, alcohol intake 
>40 g/day, concomitant hepatic comorbidities (i.e. hemochromatosis, Wilson disease, alpha1-
antitrypsin deficiency, autoimmunity) and no signed written informed consent. Additional inclusion 
criteria for the longitudinal study cohort was the availability for each patient of at least 2 serum 
samples collected within 2 years before HCC diagnosis and stored to -20°C. 
The degree of liver disease was assessed according to clinical, biochemical and histological 
criteria. Liver cirrhosis was diagnosed by liver biopsy or by laboratory data and imaging findings 
(abdominal US and transient elastography).19, 20 Diagnosis of HCC was established by CT scan and 
staging was assessed by BCLC criteria.5 
The study protocol was compliant to the Declaration of Helsinki and it was approved by the 
Institutional Ethics Committee (CEI-452). 
 
MicroRNAs quantitation 
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MiRNAs quantitation was performed by in-house developed real-time RT-PCR assay. 
Extraction was performed from 250 µL of serum by miRCURY™ RNA isolation kit - Biofluids 
(Exiqon A/S, Denmark). RNA was eluted in 50 µL of nuclease-free water and reverse transcribed using 
miRCURY LNA™ Universal RT - cDNA synthesis kit (Exiqon). The cDNA was amplified in 
duplicate using miR-specific primers and ExiLENT SYBR® Green master mix (Exiqon). Real-Time 
PCR was performed on a CFX96 thermal cycler (Bio-Rad, USA). To monitor the efficiency of 
extraction, a synthetic miRNA pool (Caernohabditis elegans [cel]-miR-39 and cel-miR-54) was spiked 
in each sample prior to RNA purification. Serum miRNA levels were calculated from cycle threshold 
(Ct) using the 2-ΔCt method and relative concentrations were expressed in “arbitrary units” (AU).  
 
AFP and PIVKA-II measurement 
Serum levels of AFP and PIVKA-II were determined on a fully automated chemiluminescent 
enzyme immunoassay (CLEIA) system, Lumipulse® G600 II analyzer (Fujirebio Europe, Gent, 
Belgium) using Lumipulse G AFP-N and Lumipulse G PIVKA-II reaction cartridges according to 
manufacturer’s instructions. AFP and PIVKA-II concentrations were given in ng/mL and mAU/mL, 
respectively. Detection limit of AFP and PIVKA-II assays were 0.075 ng/mL and 1.37 mAU/mL, 
respectively.  
 
Statistical analysis 
MiRNAs, AFP and PIVKA-II values were expressed as median and 95% confidence interval 
(CI). D’Agostino-Pearson test was used to test data normality. Mann-Whitney test and Fisher’s exact 
test were used to compare continuous and categorical variables, respectively. To evaluate diagnostic 
performance of miRNAs, AFP, PIVKA-II alone or in combination, area under the curve (AUC), 
sensitivity (Se), specificity (Sp), positive likelihood ratio (+LR) and negative likelihood ratio (-LR) 
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were assessed by using receiver operating characteristic (ROC) curves analysis. Predicted probabilities 
calculated by logistic regression model, including miRNAs, AFP and PIVKA-II as independent 
variables and HCC presence as dependent variable, were used for ROC analysis in order to evaluate the 
performance of the combination of the three biomarkers. 
Non-parametric Friedman test was used to evaluate biomarkers kinetics. Cox proportional-
hazards regression was performed to calculate univariate and multivariate Hazard Ratios (HR) of HCC 
development. The comparison between survival curves was performed by the Kaplan-Meier method 
with a log-rank test.  
A two-tailed P<0.05 was considered statistically significant. All statistical analyses were 
performed using MedCalc software, version 12.7.0.0. (MedCalc, Ostend, Belgium). 
 
Results 
Cross-sectional analysis 
Overall 63 subjects were included in the cross-sectional cohort: 30 patients with HBV-related 
cirrhosis (19 male [M], 11 female [F]; median age 54 [50-58] years) and 33 patients with a diagnosis of 
HBV-related HCC (29 M, 4 F; median age 63 [62-64] years). Patients’ characteristics are reported in 
Table I. Median miR-122, AFP and PIVKA-II serum levels of patients with cirrhosis and those with 
HCC are depicted in Figure 1. 
MiR-122 showed a moderate diagnostic accuracy for the discrimination between cirrhosis and 
HCC (AUC=0.675). The cut-off that maximized Se and Sp was 35.8 AU (Se=0.61, Sp=0.76, +LR=2.53 
and –LR=0.52). Conversely, an higher performance was observed for AFP and PIVKA-II (AUC=0.791 
and AUC=0.846, respectively). The cut-off that maximized Se and Sp for the detection of HCC among 
patients with cirrhosis was 9.5 ng/mL for AFP (Se=0.61, Sp=0.87, +LR=4.70 and –LR=0.45) and 58 
mAU/mL for PIVKA-II (Se=0.91, Sp=0.71, +LR=3.13 and –LR=0.13). 
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The combination of the 3 biomarkers into a model providing probability (P) of HCC, further 
increased the diagnostic accuracy (AUC=0.918). Mean P (HCC) values were 0.22 (0.15-0.28) in 
patients with cirrhosis and 0.90 (0.76-1.00) in those with HCC (P<0.001). The cut-off that maximized 
Se and Sp was 0.39 (Se=0.91, Sp=0.88, +LR=7.58 and –LR=0.10) (Figure 2). 
 
Longitudinal analysis  
The longitudinal study cohort included 13 HBsAg-positive patients (11 M, 2 F; median age 63 
[61-67] years) with cirrhosis under surveillance who developed HCC within the study period (Table I). 
For all patients, 3 serum samples corresponding to different time-points were analyzed: HCC diagnosis 
or T0, median 7.8 (range 4.9-11.2) months or T-1 and median 15.0 (range 13.2-19.3) months or T-2, 
before HCC diagnosis. Serum levels of MiR-122, AFP and PIVKA-II were 29.7 (10.0-76.7) AU, 5.5 
(4.2-12.7) ng/mL and 68 (60-93) mAU/mL at T-2, 15.8 (6.2-63.3) AU, 6.2 (4.6-22.7) ng/mL and 73 
(42.1-115.6) mAU/mL at T-1, and 13.0 (5.3-94.5) AU, 9.8 (5.4-216.9) ng/mL and 69 (53-240) 
mAU/mL at T0, respectively. No significant variation was observed for each single biomarker (miR-
122, P=0.163; AFP, P=0.170; PIVKA-II, P=0.447) over time. Whereas, when we analyzed P(HCC) 
trend using the 3 biomarkers combination, we obtained a statistically significant variation (P=0.011). 
Mean P (HCC) values were 0.44 (0.34-0.56) at T-2, 0.53 (0.24-0.94) at T-1 and 0.73 (0.48-0.99) at T0 
(Figure 3). 
 
Prediction of HCC development 
We found no difference of P (HCC) between cross-sectional and longitudinal (T0) HCC patients 
(0.90 [0.76-1.00] vs. 0.73 [0.48-0.99], P=0.087), whereas a significant difference was observed 
between cross-sectional and longitudinal (both T-1 and T-2) patients with cirrhosis (0.22 [0.15-0.29] vs. 
0.53 [0.24-0.94], P=0.006 and 0.22 [0.15-0.29] vs.0.44 [0.34-0.56], P=0.002, respectively). Using ROC 
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curves analysis, we identified a P (HCC) cut off value of 0.30 for the discrimination of patients who 
will develop HCC (longitudinal group at T-2) from those who will not (cirrhotic patients of the cross-
sectional group, still HCC-free at last follow-up). We obtained significantly different survival curves 
by means of this cut-off as dichotomous variable (P<0.001) (Figure 4). Multivariate Cox proportional-
hazards regression analysis, adjusted for age and gender, showed HR=10.63 (95% CI 1.87-60.28) for 
HCC development in cirrhotic patients with P(HCC) >0.30. 
 
Discussion 
The use of serum biomarkers for HCC surveillance is still debated due to lack of evidence in 
improving early HCC detection or patient outcomes.21 Nevertheless, conventional markers as AFP and 
PIVKA-II are used in clinical practice, although they are not recommended by scientific guidelines for 
their suboptimal performance.  
In recent years, there has been a growing interest to explore circulating miRNAs as potential 
biomarkers for early HCC detection.22 In the present study, carried out in patients with HBV-related 
liver disease, we found that miR-122 serum levels were significantly lower in patients with HCC 
compared to those with cirrhosis (P=0.024). This finding is in agreement with the tumor suppressor 
properties described for this miRNA. Consistently, it has been reported that miR-122 loss in HBV-
infected hepatocytes could accelerate tumorigenesis.22 Moreover, HBx protein could down-regulate 
miR-122 expression, inducing cell proliferation and release from G1/S arrest in malignant 
hepatocytes.23 
Performance of traditional biomarkers has been re-evaluated by highly sensitive CLEIA 
methods, reporting a moderate-to-good diagnostic accuracy for HCC detection, with PIVKA-II 
outperforming AFP in almost all studies (AUC=0.718-0.890 and AUC=0.618-0.829 for PIVKA-II and 
AFP, respectively).24-28 Accordingly, we found that PIVKA-II was superior to AFP (AUC=0.846 vs. 
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AUC=0.791, respectively). In addition, it has been previously demonstrated on a large group of 
patients with cirrhosis that PIVKA-II values >55mAU/mL could predict HCC development up to 18 
months before diagnosis (HR=3.71, 95% CI 1.65-8.31, P=0.002).29 
Several attempts to combine different clinical parameters with biomarkers in order to improve 
HCC surveillance effectiveness have been reported.13, 30 Johnson et al developed and validated a model 
involving gender, age, AFP-L3, AFP and DCP ("GALAD model") that showed excellent performance 
(AUC>0.9) in discriminating patients with chronic liver disease/cirrhosis from those with HCC and this 
model was also confirmed by our group.9, 12 In the present study, we found that miR-122, AFP and 
PIVKA-II combination further enhance diagnostic accuracy for HCC detection (AUC=0.918) with Se 
and Sp values approaching 0.90, being PIVKA-II the main contributing factor. Furthermore, when we 
combined these biomarkers into a model for HCC risk assessment in cirrhotic patients under 
surveillance, we found a 10-fold higher risk of HCC development up to 18 months prior cancer 
diagnosis in those with P(HCC) values >0.30. 
These preliminary results are limited by the small number of patients included in both cross-
sectional and longitudinal cohorts. Considering the actual burden of HBV infection in Italy (5-10% 
HBV-related liver disease) and the annual incidence of HCC among high risk patients (2-5%),31, 32 
these findings foster a multicenter prospective study to validate this model for monitoring changes in 
probability of HCC development.  
 
Conclusions 
Our data strengthen the added value of using biomarkers combination compared to a single 
marker for HCC detection. The use of miR-122, AFP and PIVKA-II combination into a model for HCC 
prediction (P-HCC), could provide a tool to personalize surveillance strategies, thus allowing tumor 
recognition before imaging discovery. 
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Table I.-Demographic and clinical characteristics of the patients included in the cross-sectional study 
cohort and those included in the longitudinal study cohort at time of HCC diagnosis. 
 
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; F, female; HCC, 
hepatocellular carcinoma; M, male; PIVKA-II, protein induced by vitamin k absence or antagonist II; 
Plts, platelets. 
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Figure 1.-Comparison of miR-122 (A), AFP (B) and PIVKA-II (C) serum levels between patients with 
cirrhosis and those with HCC. 
 
Abbreviations: AFP, alpha-fetoprotein; AU, arbitrary units; HCC, hepatocellular carcinoma; PIVKA-II, 
protein induced vitamin k absence or antagonist II. 
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Figure 2.-ROC curves showing the performance of miR-122, AFP and PIVKA-II alone or in 
combination for the discrimination of patients with cirrhosis and those with HCC. 
 
The equation obtained from the multiple stepwise logistic regression was: Logit(P) = -2.5336 - 0.0096 
(miR-122) + 0.0215 (AFP) + 0.0372 (PIVKA-II); where the probability (P) of HCC in a patient is 
given by: P = 1 / (1 + e-Logit(P)). Abbreviations: AFP, alpha-fetoprotein; AUC, area under the curve; 
PIVKA-II, protein induced by vitamin k absence or antagonist II. 
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Figure 3.-Longitudinal variation of miR-122 (A), AFP (B), PIVKA-II (C) and biomarkers combination 
(C) in the 13 patients with HBV-related cirrhosis that developed HCC. 
 
Friedman test was used to evaluate the kinetics of miR-122, AFP and PIVKA-II alone or in 
combination, respectively. Error bars represent the 95%CI of the median. Abbreviations: AFP, alpha-
fetoprotein; AU, arbitrary units; P(HCC), probability of hepatocellular carcinoma; PIVKA-II, protein 
induced vitamin k absence or antagonist II. 
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Figure 4.-Comparison of survival curves between patients with cirrhosis with P(HCC) value >0.30 and 
those with P-HCC ≤0.30.  
 
P-value has been calculated by Log-rank test. Abbreviations: HCC, hepatocellular carcinoma. 
